Generating a Novel High-Affinity Multi-Targeting Therapeutic Antibody for Multiple Myeloma

This project will develop a multi-targeting high-affinity mAb to treat MM, which is primarily targeted to the commercial market. By 2025 the global therapeutic mAb market is expected to generate revenue of $300 billion. Most mAbs for cancer therapy, target only one receptor/protein on the cancer cell surface, in which acquired resistance to these mAbs frequently occurs via downregulation of the antibody target from the cancer cell surface, leading to reduced clinical utility/efficacy overtime. By targeting multiple receptors with high affinity this novel mAb will exhibit enhanced clinical efficacy over existing mAbs. It is anticipated that the optimised/final candidate mAb will be deployed in various settings, including clinical and industrial settings. The key project outcomes will enable the research and development of a novel mAb and assessment of effectiveness against clinically relevant MM samples, so that GCU/Antibody Company/UoS can market this mAb, and identify requirements for further mAb innovation. The long-term outcomes of this research will positively impact clinical outcomes, such as survival and quality of life in MM patients